38: From digital microscopy to digital pathology through image analysis. How far have we come in 20 years? w/ Michael Grunkin, Visiopharm episode artwork

EPISODE · Mar 8, 2022 · 18 MIN

38: From digital microscopy to digital pathology through image analysis. How far have we come in 20 years? w/ Michael Grunkin, Visiopharm

from Digital Pathology Podcast · host Aleksandra Zuraw, DVM, PhD

Send us Fan MailVisiopharm is a company offering image analysis software used on pathology images. The software has been on the market for over 20 years and has evolved through the transition of digital microscopy to digital pathology. Digital microscopy provided static tissue images captured through the microscope camera and only branched out into digital pathology with the wider availability and adoption of whole slide scanners. Image analysis spans digital microscopy and digital pathology, and image analysis methods had to evolve in parallel with the imaging technologies to address the hypercomplex pathology problems. The complexity of digital pathology problems and research questions increases with every additional stain and scientific discovery. Visiopharm’s team challenged themselves by providing an image analysis solution capable of addressing this hypercomplexity and enabling researchers to advance scientifically with their tool. Artificial Intelligence (AI) capabilities applied to computer vision problems took tissue image analysis to a whole new level and incorporating AI into the Visiopharm software tremendously increased the accessibility of this method. In addition to the two well-known technologies that enabled digital pathology breakthroughs (whole slide imaging and AI), two other important advancements happened during the last two decades·       emphasis on interoperability between different digital pathology systems ·       advances in the field of data visualization. Together these four components are driving the progress of digital pathology both on the diagnostic and research front. During the last 20 years Visiopharm grew significantly, both organically and through funding and they continue creating value and powerful image analysis tools for the tissue image analysis community. Listen to the full episode with Visiopharm’s CEO Michael Grunkin to learn more about this 20-year perspective on what happened in the field of digital microscopy and digital pathology. Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Episode metadata supplied by the publisher feed · Published Mar 8, 2022

Embed this episode

Send us Fan Mail Visiopharm is a company offering image analysis software used on pathology images. The software has been on the market for over 20 years and has evolved through the transition of digital microscopy to digital pathology. Digital microscopy provided static tissue images captured through the microscope camera and only branched out into digital pathology with the wider availability and adoption of whole slide scanners. Image analysis spans digital microscopy and digital pathology...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

38: From digital microscopy to digital pathology through image analysis. How far have we come in 20 years? w/ Michael Grunkin, Visiopharm

0:00 18:49

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Digital Pathology Podcast?

This episode is 18 minutes long.

When was this Digital Pathology Podcast episode published?

This episode was published on March 8, 2022.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Digital Pathology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!